Concepedia

Kathryn Keenan

KK

3

Publications

294

Citations

3

H-Index

2018

Active since

Affiliations

GlaxoSmithKline (United States)(Current)

Kathryn Keenan is an author at GlaxoSmithKline (United States) specializing in drug discovery, radiation oncology, and pharmacotherapy.

Top concepts

Publications per year

2018–2021

3

Publications

3

Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia

Melissa B. Pappalardi, Kathryn Keenan, Mark Cockerill et al. · Nature Cancer · 2021 · 251 citations · Full text

, , +9

MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers

Anastasia Wyce, Jeanne J. Matteo, Shawn W. Foley et al. · Oncogenesis · 2018 · 33 citations · Full text

A Chemical Acetylation-Based Mass Spectrometry Platform for Histone Methylation Profiling

Francesca Zappacosta, Craig D. Wagner, Anthony Della Pietra et al. · Molecular & Cellular Proteomics · 2021 · 10 citations · Full text

Rows per page

1–3 of 3